Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.8400
-0.0600 (-6.67%)
May 19, 2025, 10:41 AM - Market open
Cytosorbents Revenue
Cytosorbents had revenue of $8.73M in the quarter ending March 31, 2025, a decrease of -10.82%. This brings the company's revenue in the last twelve months to $35.33M, down -3.69% year-over-year. In the year 2024, Cytosorbents had annual revenue of $35.59M with 14.51% growth.
Revenue (ttm)
$35.33M
Revenue Growth
-3.69%
P/S Ratio
1.43
Revenue / Employee
$237,129
Employees
149
Market Cap
52.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.59M | 4.51M | 14.51% |
| Dec 31, 2023 | 31.08M | -3.60M | -10.39% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CTSO News
- 4 days ago - Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 17 days ago - CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PRNewsWire
- 20 days ago - CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 4 weeks ago - CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program - PRNewsWire
- 4 weeks ago - CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller - PRNewsWire
- 5 weeks ago - CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America - PRNewsWire
- 6 weeks ago - CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants - PRNewsWire